TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Wound Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Length of healthy nail of at least 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail cure as measured by culture and smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Telmisartan AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Dosing Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reward association and valuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expectation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anticipation of reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential Microarray gene expression in vaginal tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Combined 12-hour rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of clinically improved patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in all-tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-leg standing test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early literacy skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Regulatory skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiver involvement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical and parasitological cure at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final cure (no relapse) at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful surgery defined by iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fine Motor Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects in remission after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone fracture incidence
Endpoint domain: Mortality/survival
Primary endpoint: Breastfeeding Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breastfeeding Duration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal glucose clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total glucose excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of reconnected pulmonary veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: microbiologically confirmed streptococcal pharyngitis episodes
Endpoint domain: Adverse events/effects
Primary endpoint: number and rate of missed adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative opiate dose administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of grade 2 hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Development of bipolar or schizophrenia disorder
Endpoint domain: Mortality/survival
Primary endpoint: Change in lean leg mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stair climbing power test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mixed muscle fractional synthesis rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diabetes/prediabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in prostate cancer bone involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resistance of Ocular Flora to Antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Polyethylene Inlay Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Margin Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of the number of cases achieving follicular growth to the size of mature follicle ≥ 18 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of Luteal function as assessed by mid-luteal serum progesterone measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of Endometrial thickness (mm) on the day of hCG triggering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of skin texture from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time from first outpatient appointment to decision to treat
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Descriptive analysis of joint erosions and destruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Composite Lobene Stain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: freedom from all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Procedure success in absence of MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Type of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Vitamin A status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Tic Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS of intensity of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time of the first occurrence of the maximum observed plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of normal blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prevention of ketosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility/ Participation Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Mean PANSS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean PANSS Positive Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean PANSS Negative Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean PANSS General Psychopathology Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptoms of explosive mood disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Asthma Control Questionnaire (Juniper) (ACQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responsive Feeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Providing Structure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Novel Foods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: psychological questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Active and Passive range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in MADRS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mass formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alberta Stroke Program Early Computed Tomography Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of pharmacogenomics algorithm for warfarin maintenance dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-milk oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human milk intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General cervical lordosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy proportion of USG and Cole Formula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate of Napabucasin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of Acute Kidney Injury (AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Remission From Major Depressive Episode Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HDRS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of angiogenic and inflammatory growth factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Choroidal thickness (CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient perceptions of symptom management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Long-term MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Short-Form 12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Kujala knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Tegner activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Objective evaluation of the International Knee Documentation Committee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mental health symptoms during COVID-19 pandemic
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in well-being during COVID-19 pandemic
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Modified Rankin Scale (0 - 1)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amount of distal movement of the upper canine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inclination of the upper canine, second premolar and first molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angulation of the upper canine, second premolar and first molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of mesial movement of upper first molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with protective antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in Oral Nitric Oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreasing body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ADHD-Clinical Global Impression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Adult AISRS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BUN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cystatin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of common infections
Endpoint domain: Adverse events/effects
Primary endpoint: Observed Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: total atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: histomorphometric analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timeline Followback (TLFB) of drinking behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: survival status
Endpoint domain: Mortality/survival
Primary endpoint: Treatment-related mortality at 12 months after transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Difference in fat free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall efficiency of patients with neuroblastoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Severity Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent and severity of colonic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence and severity of (serious) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-free Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Alive at 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life (QOL)/Function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average change in hemoglobin A1c test (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate by RECIST v1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Oxidative markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of neuromuscular conduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anti-HEV antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Total Meibomian Gland Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Total Meibomian Gland Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to Olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Continuation of follow-up with palliative care provider after initial consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Tinnitus symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency band EEG-activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraepidermal Nerve Fiber Density (IENFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immediate sealing of suture/staple line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent change in stimulus thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in shape perception
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neonatal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bacteria isolated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Cases With Recurrence of Laryngeal Papilloma
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour ECG monitoring parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: simplified Hidradenitis Suppurativa Clinical Response (sHiSCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self Reported Hearing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self Reported Coordination
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self Reported Walking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self Reported Fine Motor Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self Reported Bowel/Bladder Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: infection of the prosthesis
Endpoint domain: Adverse events/effects
Primary endpoint: Post-Operative Pain & Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sino-Nasal symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of new genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of lung nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Smoking exposure (pack-years)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With 20% Decrease in Phenylalanine Levels From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC from time zero to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time zero extrapolated to infinite time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time zero to last time of quantifiable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Primary Lung Cancer Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in patient understanding of prognosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of myelo- and hepatotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of myelo- and hepatotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with intravenous catheter
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of patients with urinary catheter
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Blood Products Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sperm volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With All-causality Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Vital Signs Meeting Categorical Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum S100 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ProQol (Professional Quality of Life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean carotid IMT progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of Dexdor for prolonged sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Restless Legs Syndrome (RLS) in Inflammatory Bowel Disease (IBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Celiac Disease
Endpoint domain: Mortality/survival
Primary endpoint: Hemoglobin (HGB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cardiovascular (CV)-related death
Endpoint domain: Mortality/survival